Product NewsAgendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
Industry NewsNGS-Based MammaPrint BluePrint Kit Enhances Access to Personalized Treatment for Breast Cancer Patients in Europe
Industry NewsAgendia Collaborates with Institut Curie for MammaPrint BluePrint Breast Cancer Kit Co-Validation Study
Industry NewsAgendia Highlights Study Showing MammaPrint/BluePrint Tests Predict Response to Current Breast Cancer Chemotherapy and Targeted Therapy Regimens
Product NewsAgendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment, Study Finds
Industry NewsAgendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer
Product NewsPublished Study Validates Agendia's MammaPrint Test for Long-Term Prediction of Breast Cancer Outcome
Product NewsAgendia's MammaPrint & BluePrint Tests for Breast Cancer Highlighted at Personalized Medicine Conference
